Terms: = Gastric cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
75 results:
1. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
2. Biological and targeting differences between the rare kras A146T and canonical kras mutants in gastric cancer models.
Puliga E; De Bellis C; Vietti Michelina S; Capeloa T; Migliore C; Orrù C; Baiocchi GL; De Manzoni G; Pietrantonio F; Reddavid R; Fumagalli Romario U; Ambrogio C; Corso S; Giordano S
Gastric Cancer; 2024 May; 27(3):473-483. PubMed ID: 38261067
[TBL] [Abstract] [Full Text] [Related]
3. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
4. The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer.
Xie M; Zhang L; Han L; Huang L; Huang Y; Yang M; Zhang N
Oncogene; 2023 Nov; 42(46):3435-3445. PubMed ID: 37805663
[TBL] [Abstract] [Full Text] [Related]
5. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.
Yuan T; Zhang S; He S; Ma Y; Chen J; Gu J
Sci Rep; 2023 Sep; 13(1):15916. PubMed ID: 37741901
[TBL] [Abstract] [Full Text] [Related]
6. Clinically conserved genomic subtypes of gastric adenocarcinoma.
Jeong YS; Eun YG; Lee SH; Kang SH; Yim SY; Kim EH; Noh JK; Sohn BH; Woo SR; Kong M; Nam DH; Jang HJ; Lee HS; Song S; Oh SC; Lee J; Ajani JA; Lee JS
Mol Cancer; 2023 Sep; 22(1):147. PubMed ID: 37674200
[TBL] [Abstract] [Full Text] [Related]
7. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic gastric cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract] [Full Text] [Related]
8. The Relationship Between Gene Mutations and the Clinicopathological Features and prognosis of gastric cancer.
Nie Z; Zeng K; Yan Q; Liu Y; Bian Y; Zhu J; Guo Z; He F; Shi H; Guo Y
Int J Surg Pathol; 2024 May; 32(3):486-495. PubMed ID: 37545327
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract] [Full Text] [Related]
10. [Landscape of kras, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable gastric cancer].
Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
[TBL] [Abstract] [Full Text] [Related]
11. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic cancer Undergoing Neoadjuvant Chemotherapy.
Kokumai T; Omori Y; Ishida M; Ohtsuka H; Mizuma M; Nakagawa K; Maeda C; Ono Y; Mizukami Y; Miura S; Kume K; Masamune A; Morikawa T; Unno M; Furukawa T
Mod Pathol; 2023 May; 36(5):100102. PubMed ID: 36788090
[TBL] [Abstract] [Full Text] [Related]
12. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
13. Driver and targetable alterations in Chinese patients with small bowel carcinoma.
Li J; Li X; Dong N; Yan S; Jing C; Ma T; Li W; Zhang C; Cai Y; Deng W
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6139-6150. PubMed ID: 36680582
[TBL] [Abstract] [Full Text] [Related]
14. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract] [Full Text] [Related]
15. OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome.
Pandian J; Panneerpandian P; Sekar BT; Selvarasu K; Ganesan K
Funct Integr Genomics; 2022 Dec; 22(6):1345-1360. PubMed ID: 35987846
[TBL] [Abstract] [Full Text] [Related]
16. The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer.
Yan A; Chen Y; Bian R; Wang C; Que H; Shen Y; Lu X
Cancer Med; 2023 Jan; 12(2):2046-2057. PubMed ID: 35801342
[TBL] [Abstract] [Full Text] [Related]
17. Characterization of RNA modifications in gastric cancer to identify prognosis-relevant gene signatures.
Chen Q; Liu Z; Tan Y; Pan S; An W; Xu H
Cancer Med; 2023 Jan; 12(1):879-897. PubMed ID: 35635121
[TBL] [Abstract] [Full Text] [Related]
18. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets.
Puccini A; Poorman K; Catalano F; Seeber A; Goldberg RM; Salem ME; Shields AF; Berger MD; Battaglin F; Tokunaga R; Naseem M; Zhang W; Philip PA; Marshall JL; Korn WM; Lenz HJ
Oncogene; 2022 Jun; 41(26):3455-3460. PubMed ID: 35618879
[TBL] [Abstract] [Full Text] [Related]
19. kras mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.
Shimozaki K; Shinozaki E; Yamamoto N; Imamura Y; Osumi H; Nakayama I; Wakatsuki T; Ooki A; Takahari D; Ogura M; Chin K; Watanabe M; Yamaguchi K
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1273-1283. PubMed ID: 35438321
[TBL] [Abstract] [Full Text] [Related]
20. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
[Next]
